United States

Parexel continues to expand Site Alliance Network

Wednesday, February 18, 2015 11:51 AM

Parexel International, a global biopharmaceutical services provider, has announced the continued expansion of its clinical trial Site Alliance Network, an extensive network of investigator sites and site management organizations (SMOs) that enables Parexel to quickly access and enroll patient populations for clients' clinical trials worldwide.

More... »


Clinical trials consultant, author Karen Woodin will be missed

Tuesday, February 17, 2015 10:23 AM

Karen Estelle Woodin, Ph.D., known in the clinical trials industry as a long-time industry consultant and author, passed away last week after a short bout with malignant endometrial cancer.  She was 74.

More... »


UT Southwestern to establish Center for Heavy Ion Radiation Therapy

Thursday, February 12, 2015 01:07 PM

UT Southwestern Medical Center is leading a Texas consortium of researchers to establish the country's first National Center for Heavy Ion Radiation Therapy that could provide clinical care and research using heavy particles for innovative new cancer treatments.

More... »

Biorasi adds endocrinology division, to hire 30

Thursday, February 12, 2015 01:02 PM

Biorasi, a full-service CRO powered by ProAct+, has formed an endocrinology division established to consolidate and expand Biorasi market leadership in running clinical trials in diabetes and women’s health. The new division will be led by Bill Doyle, the division manager, out of the Miami, Fla. headquarters.

More... »

Advanced Inhalation Therapies receives Orphan Drug designation Cystic Fibrosis treatment

Wednesday, February 11, 2015 03:04 PM

The FDA has granted Orphan Drug designation to AIT-CF, Advanced Inhalation Therapies' (AIT) proprietary high dose formulation of nitric oxide (NO) for adjunctive treatment of cystic fibrosis (CF). In the U.S., Orphan Drug designation provides a variety of incentives, including seven years of market exclusivity, should AIT-CF receive FDA approval.

More... »

Panacea Pharmaceuticals engages Accelovance for clinical development

Wednesday, February 11, 2015 12:46 PM

Panacea Pharmaceuticals, based in Gaithersburg, Md., and Accelovance, a CRO headquartered in Rockville, Md., have established a clinical development services agreement to develop and advance Panacea's oncology immunotherapy pipeline. Accelovance will support Panacea's clinical development strategies by offering scientific/medical and regulatory experience, in addition to providing CRO support through project management, clinical monitoring, data management, biostatistics and safety services for Panacea's clinical trials.

More... »

Lurie Cancer Center, NMDTI, Northwestern Memorial launch new research program

Friday, February 6, 2015 12:25 PM

The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, in collaboration with the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) and Northwestern Memorial Hospital, has launched a new research program, Northwestern Onco-SET (Sequence, Evaluate, Treat), to provide a more personalized, precision medicine option for cancer patients by combining oncology with genomics. This program initially will focus on patients with any type of cancer that is not responsive to traditional therapies.

More... »

Vyvanse is FDA-approved for moderate to severe binge eating disorder

Thursday, February 5, 2015 01:29 PM

The FDA has approved Shire’s Vyvanse (lisdexamfetamine dimesylate) Capsules (CII), the first and only medication for the treatment of moderate to severe binge eating disorder (BED) in adults, shown to significantly reduce the mean number of binge days per week. Vyvanse is not indicated or recommended for weight loss or the treatment of obesity. Other sympathomimetic drugs used for weight loss have been associated with serious cardiovascular reactions.

More... »

Lubrizol, Cleveland Clinic ink collaboration to advance medical innovation

Thursday, February 5, 2015 12:12 PM

Lubrizol and Cleveland Clinic announce that as part of a new joint collaboration, Lubrizol LifeSciences and Cleveland Clinic Innovations are aiming to identify—and ultimately speed the development of—new, groundbreaking products for the medical device and pharmaceutical industries.

More... »

Obama outlines his Precision Medicine Initiative

Friday, January 30, 2015 12:31 PM

Building on President Obama’s announcement in his State of the Union Address, the administration is unveiling details about the Precision Medicine Initiative, a new research effort to revolutionize how to improve health and treat disease.

More... »

`

CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs